DOI:

Discover the new country in the Valve for Life initiative, Portugal.

Discover the new country in the Valve for Life initiative, Portugal.

Keep up to date on what has been achieved so far, the challenges and expectations for 2017

Rui Campante Teles, APIC President

The Portuguese population is one of the oldest in Europe. Currently, there are around one million individuals over the age of 75. Around 3.4% of this population present with severe aortic stenosis, with about 75% being symptomatic. It is estimated that in 2015 only about 19% of potential beneficiaries actually received TAVI, and the TAVI/AVR ratio is as low as 1:6 compared to several other European countries which have already reached rates of 1:1.

There were 27 catheterisation laboratories in Portugal in 2016 with 95% of the TAVI activity performed in public hospitals. Most centres with fully operational catheterisation laboratories are part of the public health system and are thus financed by the yearly state budget for healthcare.

After the launch of the Valve for Life initiative in 2015 in Poland and France, it was decided to extend the initiative to Portugal at the beginning of 2017 under the umbrella of the Portuguese Society of Cardiology. The Oversight Committee of the initiative is confident that it can promote the use of this technology in Portugal, increasing the number of TAVI procedures. The efforts of this initiative seem promising and the prospect of duplicating the success of the other participating countries seems realistic.

In Portugal, one of the first objectives of the initiative will be to raise public awareness of the symptoms of valvular heart disease and aortic stenosis while underlining the benefits of currently available treatments. This will allow an increase in the diagnosis of the disease, eventually helping to improve access to treatment. At the same time, it will ensure hospital and cathlab capacity and funding while increasing research and analysis of scientific evidence, including clinical studies for approaches to sedation. A variety of surveys will be undertaken along with a public media campaign. Educational and other meetings and events will be planned. We are also in contact with the Portuguese Medical Association and engaged in meeting with the relevant state health officials.

Rui Campante Teles, FESC

President, APIC- Associação Portuguesa de Intervenção Cardiovascular

VFL Champions: Lino Patrício and Rui Campante Teles

Contact details: APIC - Associação Portuguesa de Intervenção Cardiovascular, Campo Grande 28, 13º, 1700-093 Lisboa, Portugal

E-mail: [email protected]

Webpage: www.valveforlife.pt

NEWS

The spotlight for the ESC Congress 2017 is on “40 years of PCI”! Young clinicians can submit their clinical cases by 1 March 2017 with the late-breaking science submissions open early March. Check it out!

Join the EAPCI Young LinkedIn group: boost your network and stay informed on educational opportunities all year long!

Learn more on EAPCI and its activities on: www.escardio.org/eapci

Volume 12 Number 14
Feb 20, 2017
Volume 12 Number 14
View full issue

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00029 Aug 4, 2025
Coronary sinus Reducer for the treatment of refractory angina: how much more evidence do we need?
Al-Lamee R and Foley M
free

Expert Review

10.4244/EIJ-D-24-00812 Aug 4, 2025
Management of device embolisation during left atrial appendage closure
Kefer J et al

Research Correspondence

10.4244/EIJ-D-24-01123 Aug 4, 2025
Coronary sinus narrowing for the treatment of refractory angina: one-year results of the REDUCER-I study
Verheye S et al

Editorial

10.4244/EIJ-E-25-00030 Aug 4, 2025
Expanding the boundaries of M-TEER: is it time to treat moderate secondary mitral regurgitation?
Adamo M and Riccardi M
free

Original Research

10.4244/EIJ-D-24-01174 Aug 4, 2025
Transcatheter valve repair of tricuspid regurgitation: 1-year outcomes from the TriCLASP study
Baldus S et al
Trending articles
224

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
172.65

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
81.4

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
49.6

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
49.6

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
23.7

Expert review

10.4244/EIJ-D-18-01180 Feb 20, 2020
Technical aspects in coronary sinus Reducer implantation
Giannini F et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved